BNT324

DRUG3 trials

Sponsors

BioNTech SE

Conditions

Advanced Lung CancerMetastatic Castration-resistant Prostate Cancer

Phase 1

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

RecruitingNCT06892548

BioNTech SEAdvanced Lung Cancer

Start: 2025-05-02End: 2031-06-01Target: 594Updated: 2026-03-19

A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer

Not yet recruitingCTIS2024-520238-31-01

BioNTech SEAdvanced Lung Cancer

Target: 26Updated: 2026-02-24

Phase 3

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Not yet recruitingNCT07365995

BioNTech SEMetastatic Castration-resistant Prostate Cancer

Start: 2026-03-01End: 2031-02-01Target: 736Updated: 2026-01-26